Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7bce595c861dba361078ba893e4713be http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_975fa00c9897abc1cbcf25acb9b74f52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_469140a5ee37d48a8d90216dc7ca2c16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_71703afe792f869887c4c3cbb7614194 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-999 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2307 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2302 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0634 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0639 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-335 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-74 |
filingDate |
2011-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb5688d12ae5b933b8d4f22853aa02c6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b87b2702fcb544973f6d7a9c8835ad1e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12d9154618f587300b3cf7ab9400e0ef |
publicationDate |
2012-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2012054792-A2 |
titleOfInvention |
Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells |
abstract |
Methods for the ex vivo generation of cells of the innate (NKT cells and NK cells) and adaptive (T cells) immune systems for use in adoptive cell transfer (ACT) are provided. The NKT cells render T cells resistant to immune suppression (e.g. they are resistant to the effects of myeloid-derived suppressor cells (MDSCs)). The method involves culturing disease- primed immune cells (obtained from a cancer patient or from a patient with an infectious disease) with i) byrostatin and ionomycin (B/I) to activate and differentiate the cells; followed by sequentially culturing the cells with a) a combination of IL-7 and IL-15 and then b) IL-2, to further differentiate the cells and to render them immune resistant. The resistant immune cells are used to treat and prevent cancer and infectious diseases. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105163745-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2521562-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11077141-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018510644-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9114157-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9545444-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014035695-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7252383-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9844569-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10166256-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10716809-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2521562-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016509840-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11679128-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018080199-A |
priorityDate |
2010-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |